{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 85,
        "end": 99
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 131,
        "end": 135
      }
    },
    {
      "id": "T4",
      "obj": "Chemical",
      "span": {
        "begin": 205,
        "end": 234
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 205,
        "end": 213
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26743855_3",
  "text": "METHODS : From 2006 to 2013 , we retrospectively screened 104 unresectable stage III adenocarcinoma patients who were examined for EGFR mutation status and received definitive concurrent CRT consisting of platinum doublet chemotherapy in first-line setting and compared the clinical outcomes and recurrence patterns according to mutation status ."
}
